Cover Image
Market Research Report
Product code 
942918

Canada Breast Cancer Diagnostics And Therapeutics Market 2019-2025

Published: | Orion Market Research Pvt Ltd | Delivery time: 2-3 business days

Price

Back to Top
Canada Breast Cancer Diagnostics And Therapeutics Market 2019-2025
Published: February 21, 2020
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Canada Breast Cancer Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (DCIS, IDC, TNBC), Inflammatory Breast Cancer and Others), By Diagnostics (Mammography, Biopsy, PET/CET, Ultrasound, and Others), By Therapeutics(Laboratory testing and Point of care testing) and Forecast 2019-2025

Canada breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.1% during the forecast period. The factors that influence the market growth in Canada include increasing the screening test for breast cancer and prevalence due to changes in life style. Breast cancer is the second leading cause of mortality in Canada. The incidence rate of breast cancer in Canada slightly increases with the increase in years. According to the Canadian Cancer Society about 26,300 women diagnosed with breast cancer in 2017. This accounts for 25% of all new cancer cases in women. The mortality due to breast cancer was about 5,000, which is 13% of all cancer mortality in women. On average 72 women in Canada were diagnosed and 14 women died with breast cancer every day. The breast cancer also happened in men about 230 men were diagnosed and mortality about 60 from breast cancer in 2017.

Canada breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

The companies which are contributing to the growth of the Canada breast cancer diagnostics and therapeutics market include, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Hologic Inc., Halozyme, Inc, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc.and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of Canada breast cancer diagnostics and therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Canada breast cancer diagnostics and therapeutics Market Research and Analysis by Cancer Type

2. Canada breast cancer diagnostics and therapeutics Market Research and Analysis by Diagnostics

3. Canada breast cancer diagnostics and therapeutics Market Research and Analysis by Therapeutics

The Report Covers:

  • Comprehensive research methodology of the Canada breast cancer diagnostics and therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Canada breast cancer diagnostics and therapeutics market.
  • Insights about market determinants which are stimulating the Canada breast cancer diagnostics and therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Product Code: OMR2020956

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Canada Breast Cancer Diagnostics and Therapeutics Market by Cancer type
    • 5.1.1. Ductal Carcinoma In-Situ (DCIS)
    • 5.1.2. Invasive Ductal Carcinoma (IDC)
    • 5.1.3. Triple Negative Breast Cancer (TNBC)
    • 5.1.4. Inflammatory Breast Cancer
    • 5.1.5. Others (Invasive lobular carcinoma)
  • 5.2. Canada Breast Cancer Diagnostics and Therapeutics Market by Diagnostics
    • 5.2.1. Mammography
    • 5.2.2. Biopsy
    • 5.2.3. PET/CET
    • 5.2.4. Ultrasound
    • 5.2.5. Others (MRI)
  • 5.3. Canada Breast Cancer Diagnostics and Therapeutics Market by Therapeutics
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormone Therapy
    • 5.3.3. Targeted Therapy
    • 5.3.4. Others (Radiation Therapy, Surgery)

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Astellas Pharma Inc.
  • 6.3. Bristol-Myers Squibb Co.
  • 6.4. Eli Lilly and Co.
  • 6.5. Hologic Inc.
  • 6.6. Halozyme, Inc
  • 6.7. Johnson & Johnson Services Inc.
  • 6.8. Merck & Co., Inc.
  • 6.9. Pfizer Inc.
  • 6.10. Siemens Healthcare GmbH

List of Tables

  • 1. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
  • 2. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)
  • 3. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)

List of Figures

  • 1. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
  • 2. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)
  • 3. CANADA BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)